
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is positioned to experience strong long-term growth in the range of 10%-14%, driven by the opportunities for their recent PMAs (AMDS and Nexus) and their pipeline of products, including Arcevo and product line extensions of Nexus. The company's main risks include potential tariffs and exposure to corruption as it continues to expand globally, and potential regulatory challenges surrounding their tissue preservation services and sterilization methods. However, we remain positive on the company's outlook and believe its current valuation presents an attractive buying opportunity.
Bears say
Artivion is facing challenges in the Medical Devices segment due to delays in FDA approval and financial hurdles for their products. This has resulted in a reduction in revenue guidance for 2026. Additionally, the use of free cash flow for future earn-outs and debt repayment may limit the company's ability to generate profits. The potential launch of NEXUS in 2027 could provide a positive impact, but the company may still face challenges in terms of onboarding new accounts and dealing with the financial commitment required for product usage.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares